CRMD: CorMedix Inc. Stock

by  •  • Comments Off on CRMD: CorMedix Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 738.44
Enterprise Value ($M) 703.16
Book Value ($M) 58.71
Book Value / Share 0.97
Price / Book 12.58
NCAV ($M) 54.28
NCAV / Share 0.89
Price / NCAV 13.60

Profitability (mra)
Return on Invested Capital (ROIC) -0.78
Return on Assets (ROA) -0.56
Return on Equity (ROE) -0.66

Liquidity (mrq)
Quick Ratio 3.60
Current Ratio 3.96

Balance Sheet (mrq) ($M)
Current Assets 73.15
Assets 77.59
Liabilities 18.87
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income 0.00
Net Income 0.00
Earnings Per Share Basic And Diluted n/a

Cash Flow Statement (mra) ($M)
Cash From Operations 0.00
Cash from Investing 0.00
Cash from Financing 0.00

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
11-14 13G/A Nomura Holdings Inc 0.30 -94.25
02-13 13G Vanguard Group Inc 5.15
01-29 13G BlackRock, Inc. 6.40 449.99

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-10-30 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 ☐ TRANSITION REPO
2024-08-14 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 ☐ TRANSITION REPORT PU
2024-05-09 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT P
2024-03-12 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTIO

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2025-01-21 210,662 1,130,481 18.63
2025-01-17 360,905 1,590,126 22.70
2025-01-16 339,205 1,581,729 21.45

(click for more detail)

Similar Companies
CLSD – Clearside Biomedical, Inc. CLYM – Climb Bio, Inc.
CMRX – Chimerix, Inc. CRON – Cronos Group Inc.
CRSP – CRISPR Therapeutics AG


Financial data and stock pages provided by
Fintel.io

Finpedia: CorMedix